NHS skin cancer vaccine halves risk or dying or disease returning, study shows

In the longest study yet, melanoma patients given the personalised vaccine alongside the immunotherapy drug Keytruda were half more likely to be alive three years later.In the longest study yet, melanoma patients given the personalised vaccine alongside the immunotherapy drug Keytruda were half more likely to be alive three years later.Read MoreHealth News | Mail Online